| 22
April 2005
Northbank continues rise in PR Week League Table
In the 2005 PR Week League Table, Northbank Communications, specialists in science-based communications, achieved a 38% increase in its income from public relations activities, moving up the rankings by seven places.
This reflects the Company’s investment in senior staff and client growth. It has added two new senior hires in the last twelve months and is winning new clients every month.
Commenting on the achievement, Sue Charles, CEO said, "We have built a strong offering for science-based companies and with public relations services as a key activity.
Most clients in our sector – biotech companies for example, need corporate, financial, scientific and medical PR all rolled into one seamless communications service, in order to attract the attention of investors and potential big pharma partners."
As well as PR, Northbank offers design and marketing services, including web and corporate materials design.
"These days, creative PR campaigns often need information-based web sites and technical factsheets to back up the interest that media comment has created. There is less of a divide between PR and other communications disciplines than there was. Indeed it is our ability to integrate campaigns and come up with the right solution for our clients that sets us apart from PR purists" Charles explains.
Northbank has focused PR practise areas in corporate communications, financial communications and marketing communications. It has a combination of retained and project clients from across Europe and the USA, and represents most of its clients on a global basis. Client retention rate has been almost 100% over the last 12 months with retained clients including Ablynx, Atugen, Biacore International, BioInvent International, CeNeS Pharmaceuticals, Cobra Biomanufacturing, IntegraGen, Medical Futures, MNLpharma, Oxagen, Oxford BioMedica, Oxford Immunotec, Peakdale Molecular, Physiomics, Plethora Solutions, PowderMed, Santaris Pharma, Scil Technology, SETsquared Partnership, Sigma-Aldrich, Solexa, Symphogen, West Pharmaceutical Services and York Pharma.
back
to news
|
